Lung Cancer

Study data from the United States, France and Japan provide new insights into lung cancer

Published in Hospital Business Week, February 4th, 2007

Studies from the United States, France and Japan yield new lung cancer data.

Study 1: Oxaliplatin with docetaxel is active well tolerated in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).

According to recent research from the United States, "Platinum-based doublets are recommended as treatment for advanced or metastatic NSCLC; however, chemotherapy must be tailored to limit side effects. A phase II study was conducted to evaluate the efficacy and safety of oxaliplatin combined with docetaxel for NSCLC. Patients with stage IIIB or IV, chemotherapy-naive NSCLC received docetaxel 70 mg/m², oxaliplatin 130...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hospital Business Week

Source: Hospital Business Week (2007-02-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry